Genotype-Guided Therapies for Hypertension in Minority Populations Across the U.S.

Hypertension is a prevalent and significant risk factor for cardiovascular disease, disproportionately affecting minority populations in the United States, particularly African American and Hispanic communities. Traditional antihypertensive therapies often fail to account for genetic variability, leading to suboptimal outcomes and contributing to health disparities. This research explores the potential of genotype-guided therapies to improve hypertension treatment outcomes in these minority populations. By analyzing genetic variants that influence the efficacy of common antihypertensive drugs, we aim to develop personalized treatment protocols tailored to individual genetic profiles. Our study revealed key genetic differences between African American and Hispanic populations, such as the higher prevalence of the CYP2C9 variant in African Americans and the ACE variant in Hispanics. Clinical trials showed that genotype-guided therapy resulted in more significant reductions in blood pressure compared to standard care. Specifically, African Americans and Hispanics in the genotype-guided group experienced blood pressure reductions of 15 mmHg and 12 mmHg, respectively. These findings suggest that implementing genotype-guided therapies could play a critical role in reducing health disparities and advancing precision medicine in cardiovascular care. Future research should focus on expanding genetic testing accessibility and exploring additional genetic variants that may influence drug responses in other populations.